Floyd Mayweather Jr. talks breaking into real estate: 'I work hard to build my name'
The boxing gloves are off, and Floyd Mayweather Jr. is sparring with a formidable foe: New York real estate.
The boxing legend talked about his detour into real estate at The Real Deal's annual NYC Forum. He's executed hundreds of millions of dollars in deals through his firm, Vada Properties — named for his home state of Nevada.
'I've always been a risk taker,' Mayweather declared with the same confidence that defined his boxing career. 'It's paid off great thus far.'
TRD's Suzannah Cavanaugh, Floyd Mayweather Jr. and Vada Properties CEO Ayal Frist (Alive Coverage)
His portfolio spans several corners of real estate: retail properties, luxury rentals, the former Versace mansion and a $400 million investment in affordable housing. Working alongside business partner Ayal Frist, Mayweather focuses on strategic investments where stable cash flow and a chance at generating 'generational wealth' exist.
Mayweather's real estate pivot originated with a courtside encounter at a New York Knicks game in the form of a chance meeting with real estate mogul Jeff Sutton and former SL Green president Andrew Matthias. One thing led to another and the pugilist started putting his money towards properties.
'It's time for me to get my feet wet,' Mayweather decided, initially making seven-figure investments before graduating to eight and nine-figure deals while still actively fighting. 'I was getting money from two different places.'
Mayweather didn't detail how hands-on he is with Vada, but noted how he had a lot of input in the company while being sure to surround himself with smart people.
One of those associations is particularly controversial; Jona Rechnitz pleaded guilty to bribing NYPD officers and has faced other legal peril. Mayweather remained steadfast in his support.
TRD's Suzannah Cavanaugh, Floyd Mayweather Jr. and Vada Properties CEO Ayal Frist (Alive Coverage)
'I'm not here to judge anyone,' he stated firmly, referring to Rechnitz as 'one of the key pieces to the puzzle.'
When questioned about rumors concerning his financial status, Mayweather responded with characteristic swagger, noting how nice it must be to be bankrupt with two private jets and hundreds of millions invested.
Mayweather also demurred discussing recently-filed defamation lawsuit targeting reporting by Business Insider, besides pointing out that this was the first time he's sued a media outlet.
'I'm not a liar,' Mayweather said. 'I work hard to build my name and build my reputation.'
Now, with his son and two daughters — both studying real estate — Mayweather isn't just building a portfolio; he's creating a real estate legacy.
As his business partner Ayal observed, Mayweather 'wrote his own playbook' in real estate, just as he did in boxing. That playbook could soon include investments in multifamily and hospitality properties in the Miami-Fort Lauderdale area this year, though Ayal cautioned against going into specifics.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Hugh Jackman and Deborra-Lee Furness are splitting their glassy $24M NYC penthouse amid their divorce
As the curtain closes on Hugh Jackman and Deborra-Lee Furness's nearly three-decade marriage, their once-shared property portfolio is beginning to follow suit — starting with a striking glass-wrapped penthouse in Manhattan's Chelsea neighborhood. Eye-catching records filed with the city on Thursday show the couple is splitting their sprawling residence at 100 Eleventh Ave., a Jean Nouvel-designed building known for its mosaic of multi-angled glass panes and dramatic architecture. The transaction took place just two days after Furness formally filed for divorce on May 23. The Real Deal first reported news of the penthouse split. The residence, for its part, was not listed for sale. While the sale price was registered at $23.6 million, the deed itself points to a significantly lower sum — approximately $11.7 million — about half of the total value. The transaction was also recorded as a sale between relatives or former relatives, according to the documentation. The buyer on the deed is listed as Phoenix Rising I LLC, which is tied to Furness and shares a Beverly Hills address with the couple's longtime legal advisors at Grant Tani Barash & Altman Inc., a law firm that appears on both sides of the deal. The name of the LLC itself — Phoenix Rising — seemingly offers a symbolic nod to post-divorce reinvention. The couple purchased the penthouse in 2022 for $21.12 million under the shell company Lackawanna LLC, the entity that appears as the seller on the most current documents for the penthouse. At that time, the deal was seen as a bold investment in a property designed by one of the world's most respected architects. Nouvel, a Pritzker Prize winner, is also the mind behind the Louvre Abu Dhabi. The three-bedroom, 3.5-bathroom home spans roughly 4,675 square feet and is lined with 14-foot-high floor-to-ceiling windows that frame sweeping vistas of the Hudson River and Manhattan skyline. Among its highlights are a private elevator entrance, a library that can convert to a fourth bedroom, and a chef's kitchen with a breakfast bar. The primary suite includes a massive dressing room and a spa-style bathroom outfitted with six fixtures. Outdoor space is equally impressive: a main-floor terrace, a loggia and a rooftop deck complete with an outdoor kitchen — all offering front-row views of the river. While the penthouse trade marks the first public sign of asset division between the two, Jackman and Furness still appear to own a triplex unit nearby in the West Village. That Perry Street property, which records show they bought in 2010, was listed for $38.9 million in 2022. StreetEasy shows it quietly came off the market in April 2024 after a series of price cuts. As of now, it remains in the Lackawanna LLC. Representatives for Furness, including family law attorney Elena Karabatos, did not immediately respond to requests for comment. A representative for Jackman also did not return a message seeking comment. Jackman, 56, and Furness, 69, announced their separation in 2023 after 27 years of marriage, citing a desire to pursue 'individual growth' while maintaining mutual respect and love. Their shocking split came a year after buying this home. Though neither party has publicly detailed the reasons behind the split, speculation swirled after Jackman's close friendship with Broadway co-star Sutton Foster drew attention during his run in 'The Music Man.' Furness broke her silence shortly after filing for divorce from Jackman last month. 'My heart and compassion goes out to everyone who has traversed the traumatic journey of betrayal,' Furness said in a statement to the Daily Mail alluding to Jackman's alleged affair. Additional reporting by Isabel Vincent
New York Post
2 days ago
- New York Post
Hugh Jackman and Deborra-Lee Furness are splitting their glassy $24M NYC penthouse amid their divorce
As the curtain closes on Hugh Jackman and Deborra-Lee Furness's nearly three-decade marriage, their once-shared property portfolio is beginning to follow suit — starting with a striking glass-wrapped penthouse in Manhattan's Chelsea neighborhood. Eye-catching records filed with the city on Thursday show the couple is splitting their sprawling residence at 100 Eleventh Ave., a Jean Nouvel-designed building known for its mosaic of multi-angled glass panes and dramatic architecture. The transaction took place just two days after Furness formally filed for divorce on May 23. The Real Deal first reported news of the penthouse split. The residence, for its part, was not listed for sale. 8 The exterior of the Jean Nouvel-designed building. Tina Gallo Photography 8 Though the sale was recorded at $23.6 million, deed records show the transaction closer to $11.7 million, indicating a split. At one point, as seen in this former listing photo, the couple enjoyed a beautiful home. Tina Gallo Photography While the sale price was registered at $23.6 million, the deed itself points to a significantly lower sum — approximately $11.7 million — about half of the total value. The transaction was also recorded as a sale between relatives or former relatives, according to the documentation. The buyer on the deed is listed as Phoenix Rising I LLC, which is tied to Furness and shares a Beverly Hills address with the couple's longtime legal advisors at Grant Tani Barash & Altman Inc., a law firm that appears on both sides of the deal. The name of the LLC itself — Phoenix Rising — seemingly offers a symbolic nod to post-divorce reinvention. The couple purchased the penthouse in 2022 for $21.12 million under the shell company Lackawanna LLC, the entity that appears as the seller on the most current documents for the penthouse. 8 The buyer is an LLC tied to Furness called Phoenix Rising I, a symbolic name suggesting a fresh start. Evan Agostini/Invision/AP At that time, the deal was seen as a bold investment in a property designed by one of the world's most respected architects. Nouvel, a Pritzker Prize winner, is also the mind behind the Louvre Abu Dhabi. The three-bedroom, 3.5-bathroom home spans roughly 4,675 square feet and is lined with 14-foot-high floor-to-ceiling windows that frame sweeping vistas of the Hudson River and Manhattan skyline. Among its highlights are a private elevator entrance, a library that can convert to a fourth bedroom, and a chef's kitchen with a breakfast bar. The primary suite includes a massive dressing room and a spa-style bathroom outfitted with six fixtures. 8 The now-former couple had purchased the 4,675-square-foot penthouse in 2022 for $21.12 million. Tina Gallo Photography 8 The home features soaring 14-foot windows, a rooftop terrace and sweeping Hudson River views. Tina Gallo Photography Outdoor space is equally impressive: a main-floor terrace, a loggia and a rooftop deck complete with an outdoor kitchen — all offering front-row views of the river. While the penthouse trade marks the first public sign of asset division between the two, Jackman and Furness still appear to own a triplex unit nearby in the West Village. That Perry Street property, which records show they bought in 2010, was listed for $38.9 million in 2022. StreetEasy shows it quietly came off the market in April 2024 after a series of price cuts. As of now, it remains in the Lackawanna LLC. 8 This bedroom retreat is both stylish and serene. Tina Gallo Photography 8 An ensuite bathroom with views of Hudson Yards. Tina Gallo Photography 8 A terrace. Tina Gallo Photography Representatives for Furness, including family law attorney Elena Karabatos, did not immediately respond to requests for comment. A representative for Jackman also did not return a message seeking comment. Jackman, 56, and Furness, 69, announced their separation in 2023 after 27 years of marriage, citing a desire to pursue 'individual growth' while maintaining mutual respect and love. Their shocking split came a year after buying this home. Though neither party has publicly detailed the reasons behind the split, speculation swirled after Jackman's close friendship with Broadway co-star Sutton Foster drew attention during his run in 'The Music Man.' Furness broke her silence shortly after filing for divorce from Jackman last month. 'My heart and compassion goes out to everyone who has traversed the traumatic journey of betrayal,' Furness said in a statement to the Daily Mail alluding to Jackman's alleged affair. Additional reporting by Isabel Vincent
Business Wire
4 days ago
- Business Wire
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services (CMS) to seek reconsideration of national Medicare coverage for VNS Therapy™ in unipolar patients with treatment-resistant depression (TRD). The first step in the process for making a National Coverage Determination (NCD) is the submission of a draft formal request for CMS reconsideration. "We have reached an important point in our pursuit to obtain national coverage for VNS Therapy for unipolar patients with depression that is difficult to treat,' said Ahmet Tezel, Ph.D., Chief Innovation Officer of LivaNova. Five critical articles featuring outcomes from in-depth data analyses on primary and select secondary endpoints in the RECOVER study have recently been published in or accepted by peer-reviewed journals, and the totality of data presented in these articles serves as the basis of the Company's request to CMS. The company believes these articles satisfy the Coverage with Evidence Development (CED) requirement of sharing peer-reviewed, publicly accessible results of pre-specified outcomes measured in the RECOVER study. In addition to the five articles, the request for coverage reconsideration includes strong 24-month clinical outcomes from the unipolar cohort of the RECOVER clinical study that demonstrate the substantial retention of benefits and the durability of VNS Therapy over time. 'We have reached an important point in our pursuit to obtain national coverage for VNS Therapy for unipolar patients with depression that is difficult to treat,' said Ahmet Tezel, Ph.D., Chief Innovation Officer of LivaNova. 'Our follow-on analyses of the RECOVER unipolar data demonstrate that symptoms alone may not be the sole source upon which to gauge the clinical impact of treatment. Instead, symptoms, function, and quality of life taken together present a more complete picture of treatment effectiveness. We are eager to review this powerful data with CMS during the reconsideration process.' Final Articles in Critical Series Analyze RECOVER Primary and Select Secondary Endpoint Data Two new in-depth analyses 1,2 on primary and select secondary endpoints in the RECOVER trial have recently been published and a third accepted by peer-reviewed journals. Prior to these articles, two initial articles were published in Brain Stimulation 3,4 in December 2024, completing the series of five critical articles in total. Collectively, the articles highlight the significant unmet need of this markedly ill population with TRD. The RECOVER data demonstrates that VNS Therapy improves symptoms, function, and quality of life in TRD patients over time. These are outcome measures identified as clinically relevant by CMS. Depressive symptoms, daily function, and quality of life taken together, as a novel composite metric, present a more complete picture of treatment effectiveness than symptoms alone. The fifth and final critical publication utilizes this composite metric and demonstrates favorable response to VNS Therapy in TRD patients who had previously failed multiple treatments, including interventional therapies. Researchers found that patients with previous ECT or TMS treatment had statistically significant and clinically meaningful benefits with active VNS Therapy. Notably, VNS Therapy is the only treatment that has demonstrated therapeutic effects in patients who previously failed ECT. 24-Month VNS Therapy Data Show Durability, Increasing Response Across All Outcome Measures New top-line 24-month data from the RECOVER study show that, across all outcome measures, VNS Therapy patients in the active arm of RECOVER experienced a substantial durability of benefit from month 12 to month 24. Of those patients who at 12 months had achieved clinically meaningful benefit, the median durability of benefit was 81.3% across all outcome measures at the 24-month assessment. This is considerable durability for these unipolar patients who, at baseline in the RECOVER study, had failed more than 13 antidepressant treatments on average. Observing all VNS Therapy patients in the active treatment arm of the RECOVER trial from month 12 to month 24, researchers also found improvement in all outcome measures, with the median rate of response, or clinically meaningful benefit, increasing from 40.2% at month 12 to 51.6% at month 24. 'There is no clinical evidence to demonstrate that there are any other therapies, including pharmacotherapies and interventional therapies such as electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS), that can claim this profound level of sustained durability and increasing benefit,' said A. John Rush, M.D., Professor Emeritus at Duke-National University of Singapore Medical School who has spent 25 years researching VNS Therapy for TRD and served as Chief Consultant on the RECOVER trial. 'These are critical findings that offer hope to treatment-resistant depression patients and their loved ones, who have struggled for years to find effective options. Patients not only stay better – they also continue to get better.' Improvement in suicidality shows statistically significant separation as early as month three LivaNova conducted additional in-depth analyses specifically evaluating suicidality for the active treatment arm of RECOVER through the first 12 months of therapy. Using a composite suicidality measure 5, results showed an estimated 43% higher odds of achieving meaningful improvement in suicidal ideation symptoms versus the control arm. Of specific interest, there was separation between the active and control arms on the composite suicidality metric as early as month three. Additionally, the observed separation was consistent throughout the initial 12 months. 'The composite suicidality outcome is especially encouraging because we can see a separation between the active and control arms so early in the study,' said Charles Conway, M.D., director of the Washington University Resistant Mood Disorders Center at Washington University School of Medicine in St. Louis. Conway is the RECOVER study's lead investigator. 'We're eager to further evaluate the suicidality data beyond 12 months and, in the context of the overall durability story of VNS Therapy, determine whether this benefit also continues to improve over time.' While not included in the initial submission to CMS, the suicidality data will be provided in detail to the agency upon publication in a peer-reviewed journal. RECOVER launched in 2019 as part of a CED framework per the CMS NCD process. For the unipolar cohort of RECOVER, enrollment was completed in March 2023, and the 12-month follow-up for those patients was completed in March 2024. No new safety issues were identified in the study. About RECOVER LivaNova's VNS Therapy™ System has been approved for the treatment of depression since earning CE Mark in 2001 and premarket approval (PMA) from the U.S. Food and Drug Administration in 2005. RECOVER stands for A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression. The largest randomized clinical study of its kind, RECOVER is examining up to 1,000 patients ages 18 or older who have unipolar or bipolar depression that is difficult to treat. A total of 493 adults with at least four documented unsuccessful attempts with antidepressant treatments participated in the unipolar cohort of the RECOVER study. The double-blind, randomized controlled study is assessing how VNS Therapy can offer patients relief from their depressive symptoms and improve quality of life. It is being carried out at up to 100 leading hospitals and medical centers across the United States. About VNS Therapy for Depression The VNS Therapy™ System, Symmetry™, is U.S. Food and Drug Administration-approved and indicated in the U.S. for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments. The most commonly reported side effects are voice alteration or hoarseness, prickling or tingling in the skin, increased coughing, shortness of breath, and sore throat. Infection is the most common complication of the surgical procedure. Important safety information is available at References Conway CR, et al. An examination of symptoms, function, and quality of life as conjoint clinical outcome domains for treatment-resistant depression. Journal of Mood & Anxiety Disorders. April 14, 2025. DOI: 10.1016/ Sackeim HA, et al. Characterizing the effects of vagus nerve stimulation on symptom improvement in markedly treatment-resistant major depressive disorder: A RECOVER trial report. July 1, 2025. DOI: 10.1016/ Conway CR, et al. Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. Brain Stimulation. Dec. 18, 2024. DOI: 10.1016/ Rush AJ, et al. Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial. Brain Stimulation. Dec. 18, 2024. DOI: 10.1016/ The composite suicidality metric was created by adding a suicidality-specific question from each of MADRS, Quick Inventory of Depressive Symptomology–Self Report, or QIDS-SR, and Quick Inventory of Depressive Symptomology–Clinical, or QIDS-C. About LivaNova LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit Safe Harbor Statement This news release contains 'forward-looking statements' concerning the Company's goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the RECOVER study, the VNS Therapy™ System, Symmetry™, and the likelihood that the Company is successful in obtaining national Medicare coverage for its VNS Therapy™ System. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
